HUP0001381A2 - Dolasztatin-15-származékok taxánokkal kombinálva - Google Patents
Dolasztatin-15-származékok taxánokkal kombinálvaInfo
- Publication number
- HUP0001381A2 HUP0001381A2 HU0001381A HUP0001381A HUP0001381A2 HU P0001381 A2 HUP0001381 A2 HU P0001381A2 HU 0001381 A HU0001381 A HU 0001381A HU P0001381 A HUP0001381 A HU P0001381A HU P0001381 A2 HUP0001381 A2 HU P0001381A2
- Authority
- HU
- Hungary
- Prior art keywords
- groups
- short
- chain alkyl
- compound
- treatment
- Prior art date
Links
- 229940123237 Taxane Drugs 0.000 title 1
- LQKSHSFQQRCAFW-CCVNJFHASA-N [(2s)-1-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical class C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229940063683 taxotere Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A találmány tárgyát rákbetegségek kezelésére szolgáló készítmények éseljárások képezik, amelyekben egy RlR2N-CHX-CO-A-B-D-(E)s-(F)t-(G)u-Káltalános képletű vegyületet - ahol R1 és R2 rövid szénláncú alkilcsoport; X adott esetben elágazó láncú, rövid szénláncú alkilcsoport; s, t és u értéke 0 vagy l; A, B, D és E különböző természetes vagy nem természetes aminosav-maradék; K R5 és R6 csoportokkal szubsztituált aminocsoport, ahol R5 hidrogénatom vagy alkoxicsoport; és R6 különböző alkil-, cikloalkil- vagy hidroxialkilcsoportok közülkiválasztott egy vegyértékű gyök - vagy ennek fiziológiailagelviselhető savakkal alkotott sóit és egy a paclitaxel, taxoter ésmódosított taxán vagy taxoid analógok közül kiválasztott vegyületetegyütt kombinációs kezelés formájában alkalmaznak. A készítménykomponensei együtt szinergetikus hatást mutatnak, azaz kombinációk azegyes komponensek tumorellenes hatását felülmúló tumorelleneshatékonyságúak. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/819,101 US6103698A (en) | 1997-03-13 | 1997-03-13 | Dolastatin-15 derivatives in combination with taxanes |
| PCT/US1998/004594 WO1998040092A1 (en) | 1997-03-13 | 1998-03-09 | Dolastatin-15 derivatives in combination with taxanes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0001381A2 true HUP0001381A2 (hu) | 2000-10-28 |
| HUP0001381A3 HUP0001381A3 (en) | 2001-12-28 |
| HU228860B1 HU228860B1 (en) | 2013-06-28 |
Family
ID=25227196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001381A HU228860B1 (en) | 1997-03-13 | 1998-03-09 | Dolastatin-15 derivatives in combination with taxanes |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6103698A (hu) |
| EP (1) | EP0981358B1 (hu) |
| JP (1) | JP2001514659A (hu) |
| KR (1) | KR100555604B1 (hu) |
| CN (1) | CN1157223C (hu) |
| AT (1) | ATE241376T1 (hu) |
| AU (1) | AU728027B2 (hu) |
| BG (1) | BG64338B1 (hu) |
| BR (1) | BR9808249A (hu) |
| CA (1) | CA2282720C (hu) |
| CO (1) | CO4940498A1 (hu) |
| CZ (1) | CZ293905B6 (hu) |
| DE (1) | DE69815100T2 (hu) |
| DK (1) | DK0981358T3 (hu) |
| ES (1) | ES2200317T3 (hu) |
| HK (1) | HK1026851A1 (hu) |
| HR (1) | HRP980125A2 (hu) |
| HU (1) | HU228860B1 (hu) |
| ID (1) | ID23900A (hu) |
| IL (2) | IL131597A0 (hu) |
| NO (1) | NO323894B1 (hu) |
| NZ (1) | NZ337416A (hu) |
| PL (1) | PL197834B1 (hu) |
| PT (1) | PT981358E (hu) |
| RU (1) | RU2218174C2 (hu) |
| SK (1) | SK285133B6 (hu) |
| TR (1) | TR199902244T2 (hu) |
| TW (1) | TWI277426B (hu) |
| WO (1) | WO1998040092A1 (hu) |
| ZA (1) | ZA982093B (hu) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010009901A1 (en) * | 1996-12-11 | 2001-07-26 | Basf Aktiengesellschaft Germany | Antineoplastic peptides |
| CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| AU2002214876A1 (en) * | 2000-11-08 | 2002-05-21 | Lorus Therapeutics Inc. | Combination preparation of a biological response modifier and an anticancer agent and uses thereof |
| US20050192443A1 (en) * | 2000-11-08 | 2005-09-01 | Lorus Therapeutics Inc. | Biological response modifier for the treatment of cancer |
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| BRPI0711591A2 (pt) | 2006-05-16 | 2011-11-16 | Aegera Therapeutics Inc | composto de ligação de domìnio bir da iap |
| AR080154A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos cd20 y su utilizacion |
| SG182724A1 (en) | 2010-02-12 | 2012-08-30 | Pharmascience Inc | Iap bir domain binding compounds |
| TW202210498A (zh) * | 2020-06-03 | 2022-03-16 | 日商中外製藥股份有限公司 | 高難度序列之有效率的胜肽縮合法 |
| JPWO2023033129A1 (hu) | 2021-09-03 | 2023-03-09 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816444A (en) * | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US5676978A (en) | 1989-02-14 | 1997-10-14 | Amira, Inc. | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent |
| US4879278A (en) * | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US5278324A (en) * | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
| MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| SG87056A1 (en) | 1991-08-09 | 2002-03-19 | Teikoku Hormone Mfg Co Ltd | Novel tetrapeptide derivative |
| US5227400A (en) * | 1991-09-23 | 1993-07-13 | Florida State University | Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them |
| US5250683A (en) * | 1991-09-23 | 1993-10-05 | Florida State University | Certain substituted taxanes and pharmaceutical compositions containing them |
| US5272171A (en) * | 1992-02-13 | 1993-12-21 | Bristol-Myers Squibb Company | Phosphonooxy and carbonate derivatives of taxol |
| FR2688518B1 (fr) * | 1992-03-13 | 1994-05-06 | Rhone Poulenc Rorer Sa | Procede de preparation de derives du taxane. |
| US5831002A (en) * | 1992-05-20 | 1998-11-03 | Basf Aktiengesellschaft | Antitumor peptides |
| US5248796A (en) * | 1992-06-18 | 1993-09-28 | Bristol-Myers Squibb Company | Taxol derivatives |
| US5254580A (en) * | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| ATE196296T1 (de) * | 1992-12-16 | 2000-09-15 | Basf Ag | Dolastatin analog |
| US5484612A (en) * | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| CA2129282A1 (en) | 1993-09-29 | 1995-03-30 | George Weber | Method for the treatment of neoplastic disease utilizing taxol and tiazofurin |
| US5447936A (en) * | 1993-12-22 | 1995-09-05 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof |
| US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
| US5494930A (en) * | 1994-06-02 | 1996-02-27 | Shimizu; Yuzuru | Caribenolide I |
| US5525613A (en) * | 1994-06-16 | 1996-06-11 | Entropin, Inc. | Covalently coupled benzoylecgonine ecgonine and ecgonidine |
| US5504191A (en) * | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5530097A (en) * | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5543423A (en) * | 1994-11-16 | 1996-08-06 | Vertex Pharmaceuticals, Incorporated | Amino acid derivatives with improved multi-drug resistance activity |
| AU699442B2 (en) | 1994-12-15 | 1998-12-03 | Baker Norton Pharmaceuticals, Inc. | Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound |
-
1997
- 1997-03-13 US US08/819,101 patent/US6103698A/en not_active Expired - Lifetime
-
1998
- 1998-03-09 EP EP98909066A patent/EP0981358B1/en not_active Expired - Lifetime
- 1998-03-09 BR BR9808249-3A patent/BR9808249A/pt not_active IP Right Cessation
- 1998-03-09 DK DK98909066T patent/DK0981358T3/da active
- 1998-03-09 JP JP53967998A patent/JP2001514659A/ja active Pending
- 1998-03-09 PT PT98909066T patent/PT981358E/pt unknown
- 1998-03-09 TR TR1999/02244T patent/TR199902244T2/xx unknown
- 1998-03-09 CZ CZ19993211A patent/CZ293905B6/cs not_active IP Right Cessation
- 1998-03-09 PL PL335579A patent/PL197834B1/pl unknown
- 1998-03-09 CN CNB988033089A patent/CN1157223C/zh not_active Expired - Fee Related
- 1998-03-09 WO PCT/US1998/004594 patent/WO1998040092A1/en active IP Right Grant
- 1998-03-09 KR KR1019997008305A patent/KR100555604B1/ko not_active IP Right Cessation
- 1998-03-09 ES ES98909066T patent/ES2200317T3/es not_active Expired - Lifetime
- 1998-03-09 AT AT98909066T patent/ATE241376T1/de active
- 1998-03-09 ID IDW991020A patent/ID23900A/id unknown
- 1998-03-09 RU RU99122032/14A patent/RU2218174C2/ru not_active IP Right Cessation
- 1998-03-09 SK SK1251-99A patent/SK285133B6/sk not_active IP Right Cessation
- 1998-03-09 IL IL13159798A patent/IL131597A0/xx active IP Right Grant
- 1998-03-09 CA CA002282720A patent/CA2282720C/en not_active Expired - Fee Related
- 1998-03-09 HU HU0001381A patent/HU228860B1/hu not_active IP Right Cessation
- 1998-03-09 NZ NZ337416A patent/NZ337416A/en not_active IP Right Cessation
- 1998-03-09 DE DE69815100T patent/DE69815100T2/de not_active Expired - Lifetime
- 1998-03-09 AU AU66945/98A patent/AU728027B2/en not_active Ceased
- 1998-03-10 HR HR08/819,101A patent/HRP980125A2/hr not_active Application Discontinuation
- 1998-03-12 ZA ZA9802093A patent/ZA982093B/xx unknown
- 1998-03-12 CO CO98013903A patent/CO4940498A1/es unknown
- 1998-03-13 TW TW087103777A patent/TWI277426B/zh not_active IP Right Cessation
-
1999
- 1999-08-26 IL IL131597A patent/IL131597A/en not_active IP Right Cessation
- 1999-09-10 NO NO19994408A patent/NO323894B1/no not_active IP Right Cessation
- 1999-09-13 BG BG103728A patent/BG64338B1/bg unknown
-
2000
- 2000-03-07 US US09/520,254 patent/US6632795B1/en not_active Expired - Fee Related
- 2000-09-26 HK HK00106074A patent/HK1026851A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0202570A1 (hu) | Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk | |
| HUP0303498A2 (hu) | Szájápoló készlet és készítmény | |
| DE69929313D1 (de) | Verfahren und zusammensetzungen zur verabreichung von taxanen | |
| DE69822659D1 (de) | Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln | |
| IL119989A0 (en) | Pharmaceutical compositions for oral treatment of multiple sclerosis | |
| ATE241323T1 (de) | Virtuelle orthodontische zahnbehandlung | |
| HUP0101564A2 (hu) | Epotilon készítmények | |
| HUP0001381A2 (hu) | Dolasztatin-15-származékok taxánokkal kombinálva | |
| DE60231123D1 (de) | Verfahren zur auslösung einer zytotoxischen immunantwort und dafür nützliche rekombinante affen-adenovirus-zusammensetzungen | |
| BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| HUP0300836A2 (hu) | Taxánokat tartalmazó szájon át beadható gyógyszerkészítmények és ezek alkalmazása | |
| TR200003048T2 (tr) | İnsülinin peptit analoglarının diyabet tedavisi için kullanımı. | |
| ATE212846T1 (de) | Bisphosphonat und anti-resorption agentien, enthaltende zusammensetzungen zur hemmung der knochenschwund | |
| ATE221059T1 (de) | Delta 12,16-isotaxol analoge mit antineoplastischer wirkung und pharmazeutische zusammensetzungen sie enthaltend | |
| DK0758231T3 (da) | Farmaceutiske præparater på basis af derivater tilhørende taxanklassen | |
| CY1110600T1 (el) | Αναλογα της βιταμινης d | |
| HUP0301817A2 (hu) | Kahalalid-vegyületek, elżállításukra szolgáló eljárás, azokat tartalmazó gyógyászati készítmények és alkalmazásuk | |
| DK0499923T3 (da) | Dentaladhæsiv | |
| BR0207699A (pt) | Produto para aplicação axilar | |
| HUP0302196A2 (hu) | Szolubilizált izzadásgátló hatóanyagot és illékony szilikont tartalmazó egyfázisú izzadásgátló készítmények | |
| ATE554753T1 (de) | 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia | |
| BG106155A (en) | Novel derivatives and analogues of galanthamin | |
| HUP0303463A1 (hu) | Dimer izoflavonok | |
| Zorlu et al. | Histomorphometric and histopathologic evaluation of the effects of systemic fluoride intake on orthodontic tooth movement | |
| HUP0303589A2 (hu) | Egy taxán és egy ciklin-dependens kináz inhibitor kombinációja |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): BELICZAY LASZLO, S.B.G. & K. BUDAPESTI NEMZETKOEZI SZABADALMI IRODA, HU Representative=s name: RATHONYI ZOLTAN S.B.G. & K. BUDAPESTI NEMZETKO, HU |
|
| FH92 | Termination of representative |
Representative=s name: BELICZAY LASZLO, S.B.G. & K. BUDAPESTI NEMZETK, HU |
|
| GB9A | Succession in title |
Owner name: ABBVIE DEUTSCHLAND GMBH & CO KG, DE Free format text: FORMER OWNER(S): BASF AKTIENGESELLSCHAFT, DE; ABBOTT GMBH & CO. KG, DE |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |